Metabolomic characterization of human hippocampus from drug-resistant epilepsy with mesial temporal seizure.
Fiche publication
Date publication
mars 2018
Journal
Epilepsia
Auteurs
Membres identifiés du Cancéropôle Est :
Pr NAMER Izzie-Jacques, Dr LHERMITTE Benoît, Dr CEBULA Hélène, Pr PROUST François
Tous les auteurs :
Detour J, Bund C, Behr C, Cebula H, Cicek EA, Valenti-Hirsch MP, Lannes B, Lhermitte B, Nehlig A, Kehrli P, Proust F, Hirsch E, Namer IJ
Lien Pubmed
Résumé
Within a complex systems biology perspective, we wished to assess whether hippocampi with established neuropathological features have distinct metabolome. Apparently normal hippocampi with no signs of sclerosis (noHS), were compared to hippocampal sclerosis (HS) type 1 (HS1) and/or type 2 (HS2). Hippocampus metabolome from patients with epilepsy-associated neuroepithelial tumors (EANTs), namely, gangliogliomas (GGs) and dysembryoplastic neuroepithelial tumors (DNTs), was also compared to noHS epileptiform tissue.
Mots clés
HRMAS NMR , hippocampal sclerosis, long-term epilepsy-associated tumor, mesial temporal lobe epilepsy, metabolomics
Référence
Epilepsia. 2018 Mar;59(3):607-616